Creepy Tale 3: Ingrid Penance

Creepy Brothers · 2023 · $9.99 · Adventure · deal grade D

Measured on 2026-10-05 12:40 UTC. The whole catalog is re-measured daily; a game that just launched can move fast between passes.

Estimated net residual revenue: $255 to $382 per month
Opportunity: $318 per month at x1.00 dormancy
Estimated lifetime owners: 30.8k
90% positive across 1055 reviews · 5.1 reviews/month

Why it's flagged

Developer active, last post 5 months ago
Studio active elsewhere (6 titles tracked), so this one may welcome a partner
Last discounted 0 months ago, 9 sales in the last 12 months
Proven demand elasticity: x1.4 review velocity during past deep sales

Analyst notes (AI-assisted)

Note written 2026-09-20; the live figures above take precedence over any numbers in it.

A 2023 dark fairy-tale adventure with hand-drawn art, puzzle-solving and light action, third in the Creepy Tale series.

Creepy Tale 3 operates in a quiet but stable niche: strong positive sentiment (90%), moderate residuals ($255-382/mo), and a loyal installed base that actively explores the studio's broader catalog. The game sits outside mainstream visibility yet sustains itself on core adventure-game fans and Eastern European interest (Russian reviews dominate). For a small publisher or studio seeking steady-revenue IP with proven sequel legs and minimal maintenance overhead, this represents a credible catalog addition; however, the ceiling is modest and growth unlikely without active marketing or significant dev investment. Most realistic play: acquisition.

Risk: Indie adventure genre is crowded; zero discounting in 12 months and absence of promotion may reflect market saturation rather than strategy.
Risk: Current player counts are minimal (3 concurrent, 15 peak 30d), signaling no multiplayer hook and limited word-of-mouth potential.
Risk: 27 months since last build and 4.5 months since dev activity; code may need updates for emerging platforms or OS compatibility.

This case as Markdown · Estimates carry ±30-50% error per title.